← Back to Screener
4D Molecular Therapeutics, Inc. Common Stock (FDMT)
Price$8.64
Value ScoreC
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-33.83%
Price vs S&P 500 (4W)-14.78%
VGM Score76.51
Market Capitalization$451.67M
All Metrics
Book Value / Share (Quarterly)$8.64
P/TBV (Annual)2.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)200.82%
Cash Flow / Share (Quarterly)$-2.47
Price vs S&P 500 (YTD)7.04%
Net Profit Margin (TTM)-182.34%
EPS (TTM)$-2.70
10-Day Avg Trading Volume0.95M
EPS Excl Extra (TTM)$-2.70
Revenue Growth (5Y)44.32%
EPS (Annual)$-2.42
ROI (Annual)-27.71%
Net Profit Margin (5Y Avg)-87851.79%
Cash / Share (Quarterly)$7.48
Revenue Growth QoQ (YoY)21664.29%
ROA (Last FY)-24.72%
Revenue Growth TTM (YoY)383560.87%
EBITD / Share (TTM)$-2.86
ROE (5Y Avg)-32.16%
Operating Margin (TTM)-203.47%
Cash Flow / Share (Annual)$-1.90
P/B Ratio1.00x
P/B Ratio (Quarterly)1.05x
Net Income / Employee (Annual)$-714,800
EV / Revenue (TTM)4.30x
ROA (TTM)-32.55%
EPS Incl Extra (Annual)$-2.42
Current Ratio (Annual)9.39x
Quick Ratio (Quarterly)9.01x
3-Month Avg Trading Volume0.77M
52-Week Price Return120.97%
Revenue / Employee (TTM)$450,200
Tangible BV / Share (Quarterly)$7.72
P/S Ratio (Annual)5.30x
Asset Turnover (Annual)0.15x
52-Week High$12.34
Operating Margin (5Y Avg)-102464.20%
EPS Excl Extra (Annual)$-2.42
CapEx CAGR (5Y)-11.73%
26-Week Price Return-25.90%
Quick Ratio (Annual)9.15x
13-Week Price Return0.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.34x
Enterprise Value$379.18M
Revenue / Share Growth (5Y)23.59%
Asset Turnover (TTM)0.18x
Book Value / Share Growth (5Y)-1.78%
Revenue / Employee (Annual)$434,700
Pretax Margin (Annual)-164.43%
Cash / Share (Annual)$6.99
3-Month Return Std Dev72.43%
Net Income / Employee (TTM)$-820,900
ROE (Last FY)-27.71%
EPS Basic Excl Extra (Annual)$-2.42
Receivables Turnover (TTM)4.92x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.70
Receivables Turnover (Annual)24.05x
ROI (TTM)-36.83%
P/S Ratio (TTM)5.12x
Pretax Margin (5Y Avg)-87851.79%
Revenue / Share (Annual)$1.47
Tangible BV / Share (Annual)$7.09
Price vs S&P 500 (52W)96.61%
Year-to-Date Return15.20%
5-Day Price Return-11.02%
EPS Normalized (Annual)$-2.42
ROA (5Y Avg)-28.87%
Net Profit Margin (Annual)-164.43%
Month-to-Date Return-12.82%
Cash Flow / Share (TTM)$-2.52
EBITD / Share (Annual)$-2.67
Operating Margin (Annual)-187.24%
ROI (5Y Avg)-32.16%
EPS Basic Excl Extra (TTM)$-2.70
P/TBV (Quarterly)1.60x
P/B Ratio (Annual)0.85x
Pretax Margin (TTM)-182.34%
Book Value / Share (Annual)$8.78
Price vs S&P 500 (13W)-8.25%
Beta2.80x
P/FCF (Annual)58.89x
Revenue / Share (TTM)$1.30
ROE (TTM)-36.83%
52-Week Low$3.68
vGradeC
gGradeA
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-1.01est. -1.01
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.12
4.12
4.12
4.12
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FDMT4D Molecular Therapeutics, Inc. Common Stock | C | A | B | $8.64 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
4D Molecular Therapeutics is a clinical-stage gene therapy company developing novel treatments using evolved AAV vectors across three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company's pipeline includes multiple product candidates targeting retinal diseases, heart conditions, and pulmonary disorders, leveraging its proprietary vector technology designed for targeted delivery and efficacy. With programs spanning intravitreal, intravenous, and aerosol administration routes, 4D is advancing a diversified approach to gene therapy development.